Last update Aug. 11, 2020

Empagliflozin

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

Empagliflozin is a selective and reversible inhibitor of the sodium and glucose co-transporter 2 (SGLT2). It has similar actions to dapagliflozin. It acts by reducing the renal reabsorption of glucose and increasing its elimination via urine (Devi 2017, Scott 2014).
Administered orally once a day.

Since the last update, we have not found published data on its excretion in breast milk.

Its pharmacokinetic characteristics (moderately elevated molecular weight, high plasma protein binding and large volume of distribution: AEMPS 2019, FDA 2016), make it very unlikely its excretion into breast milk in significant amounts.

It has low risk of hypoglycemia in monotherapy, which increases when it is associated with other hypoglycaemic agents (AEMPS 2019, FDA 2016).

Until there is more published data on this drug in relation to breastfeeding, safer known alternatives may be preferable, especially during the neonatal period and in case of prematurity.

Diet, exercise and breastfeeding improve blood glucose levels.


See below the information of this related product:

Alternatives

  • Acarbose ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Dapagliflozin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Glibenclamide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Glipizide ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Hypocaloric Diet ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Maternal Sport ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Metformin Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Miglitol ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Empagliflozin in other languages or writings:

Group

Empagliflozin belongs to this group or family:

Tradenames

Main tradenames from several countries containing Empagliflozin in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 451 daltons
Protein Binding 86 %
VD 1.05 l/Kg
pKa 12.57 -
Tmax 1.5 hours
12.4 hours

References

  1. AEMPS. Empagliflozina. Ficha técnica. 2019 Full text (in our servers)
  2. Devi R, Mali G, Chakraborty I, Unnikrishnan MK, Abdulsalim S. Efficacy and safety of empagliflozin in type 2 diabetes mellitus: a meta-analysis of randomized controlled trials. Postgrad Med. 2017 Apr;129(3):382-392. Abstract
  3. FDA. Empagliflozin. Drug Summary. 2016 Full text (in our servers)
  4. Scott LJ. Empagliflozin: a review of its use in patients with type 2 diabetes mellitus. Drugs. 2014 Oct;74(15):1769-84. Abstract

Total visits

4,634

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM